Annexon Inc. (ANNX)
ANNX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ANNX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001528115 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $102.4M cash; operating cash flow -$47.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 190,763,984 (2026-11-05); 119,632,804 a year earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-31 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Francisco, California, United States | PCAOB Form AP 2026-04-21 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $12.4M, sold $286K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$51.2M | -$48.7M | $102.4M | $49.3M | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$55.3M | -$48.0M | $199.3M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$44.1M | -$46.8M | $175.2M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$48.3M | -$45.9M | $162.1M | $0 | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$54.9M | -$52.3M | $139.4M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$49.2M | -$38.1M | $132.3M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$54.4M | -$50.1M | $97.1M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$48.6M | -$36.0M | $49.5M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-31 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 525 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.7% |
| 1 month | +2.3% |
| 3 months | -25.5% |
| Year to date | -21.9% |
| 1 year | +46.3% |
| From 52-week high | -43.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| APMD | Apnimed Inc. | $16.28 | -3.78% | $677.7M |
| JANX | Janux Therapeutics Inc. | $10.92 | -3.96% | $668.1M |
| ALMS | Alumis Inc. | $5.14 | -8.21% | $667.3M |
| NVCT | Nuvectis Pharma Inc. | $19.11 | -5.58% | $657.2M |
| KURA | Kura Oncology Inc. | $7.09 | -8.75% | $651.4M |
| BCAX | Bicara Therapeutics Inc. | $9.75 | -2.69% | $647.3M |
| ANL | Adlai Nortye Group Ltd. | $10.03 | -5.47% | $645.9M |
| OLMA | Olema Oncology Inc. | $7.36 | -2.65% | $644.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier